SERO featured in MedWatch: Growth, exports and global ambitions

SERO was recently featured in MedWatch, where CEO Stefan Kernstock shared insights into the company’s growth, export strategy, and international development.

In 2024, SERO reached NOK 186 million in revenue, an increase of NOK 20 million from the previous year. 90% of the company’s income came from exports, with growth across multiple regions and product areas.

SERO also established a subsidiary in the United States in 2022, though the American market still represents a small share of total revenue. Europe and Japan remain the company’s largest markets, and Kernstock sees continued potential in both regions.

In the interview, Kernstock also commented on Norway’s national export initiative for the health industry, emphasizing the importance of collaboration between specialized companies. He highlighted that building successful export businesses takes time, especially in the health sector.

“We’ve reinvested our profits for many years to get to where we are, and that’s necessary for companies like ours. You need to build over years, not months,” Kernstock told MedWatch.

Read the full article at MedWatch (subscription required).